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1. Introduction 
1.1 Regulation of female reproductive system 
Regulation of female reproductive system consists of very complex interactions between the 
hypothalamus, neurohypophysis and ovaries. Beginning from the embryologic stage, female 
reproductive system is regulated by the brain. Ovarian hormone production is supressed by 
the hypothalamo-hypophyseal control mechanism till the end of the childhood period when 
the puberty begins. During puberty, menstrual cyclicity and timely ovulation, which are the 
result of the precise integration within different components of the reproductive system, are 
achieved. After puberty, comes the reproductive period which generally lasts about 30-35 
years. During reproductive period, from daily social behavior to sexual life and 
reproduction, many important issues depend on normal ovarian folliculogenesis and 
hormonogenesis. Menopause refers to the final menstrual period accompanying the 
permanent cessation of ovarian function and menstruation.  
Gonadotropin releasing hormone receptor (GnRHR) is secreted from hypothalamus and 
delivered to the anterior pituitary via the hypophyseal portal circulation where it binds to 
the GnRHR on the surface of gonadotropes triggering the synthesis and secretion of the 
gonadotropins, follicle stimulating hormone (FSH) and luteinizing hormone (LH). In the 
female, LH stimulates the production of androgens by the thecal cells that surround the 
growing ovarian follicle. During the terminal stages of follicular growth, LH also drives the 
production of progesterone from the granulosa cells of the preovulatory follicle. FSH binds 
to receptors on the surface of ovarian granulosa cells stimulating the expression of 
aromatase enzymes that convert thecal androgens to estradiol. The Hypothalamus-
hypophysis-gonadal (HPG) axis is subject to both positive feed-forward and negative 
feedback regulation at several levels. At the level of the hypothalamus, early recognition of 
the pulsatile nature of gonadotropin releasing hormone secretion led to the notion of a 
central ‘‘pulse generator”, the inherent oscillatory activity of which controls the secretory 
rhythm of GnRH neurons (Knobil, 1980). Hypothalamic pulse generator is extensively 
modulated by a multitude of higher level inputs including photoperiod, environmental 
stress, metabolic state and nutritional status, as well as various endocrine mediators. (Bliss, 
2010) 
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1.2 Impact of epilepsy on female reproductive system 
Epilepsy is a neurological disorder clinically characterized by recurrent seizures ranging 
from a very mild form of disruption in attention for a few seconds, to a severe form of 
muscle spasms and loss of consciousness. Epilepsy is a major public health problem 
worldwide. The prevalence of epilepsy increases with age (Brodie et al, 2009; Wallace et al, 
1998) from 90 per 100,000 people of age 65–70 years, to 150 per 100,000 in those older than 80 
years. The treatment goals are suppression and prevention of the seizures. For these 
purposes, antiepileptic drugs (AED) are used. 
Epilepsy has a gender-related pathophysiology and consequences. Therefore, being a 
woman with epilepsy is not the same as being a man with epilepsy (Taubøll et al, 2008); in 
fact, the frequency and severity of seizures can increase on certain days of the menstrual 
cycle (Herzog et al, 1997). Seizures generally exacerbate during the 3 different periods of the 
menstrual cycle: in perimenstrual and periovulatory periods in normal cycles, and in 
inadequate luteal phase in abnormal cycles (Figure 1). This type of epilepsy is defined as 
catamenial epilepsy and is under the influence of estrogen and progesterone. Estrogen has 
been shown to increase seizure activity, while progesterone decreases it by raising the 
seizure threshold level (Frye, 2008). Progesterone is converted to allopregnanolone in the 
brain. Allopregnanolone has been suggested as a primary compound responsible for 
decreased seizure susceptibility (Scharfman and MacLusky, 2006). 
Estrogen acts as a proconvulsant in several animal models of epilepsy, including amygdalal 
kindling and pentylenetetrazol administration in ovariectomized rats (Hom and 
Buterbaugh, 1986). Estrogen induces the formation of new excitatory synapses in the CA1 
region of the hippocampus; and further, this estrogenic induction involves activation of N-
methyl-Daspartate (NMDA) receptors (McEwen, 2002). Increasing the complexity of 
hippocampal synaptic density is likely a mechanism for the proconvulsant activity of 
estrogen. Standard hormone replacement in postmenopausal women with epilepsy, which 
includes estrogen and a progestin, can be postulated to have an effect on seizures that is 
more evident than that of oral contraceptives in cycling women with epilepsy. This is 
because reproductive hormone levels during menopause are low and unchanging. 
Therefore, the brain hormonal milieu in which exogenous hormones are introduced is 
markedly different in menopause from that in menstruating women.  
In the ovariectomized animals, however, the hormonal changes in the animals are abrupt in 
contrast to the gradual hormonal changes found in the menopausal transition. It might be 
the concerted lack of estradiol and progesterone that facilitate the seizure susceptibility. 
Both estradiol and progesterone affect γ-amino butyric acid (GABA) ergic function 
(Scharfman et al, 2005; Nakumura et al, 2005; Kokate et al, 1994). The simultaneous decrease 
of estrogen and progesterone may thereby lead to a decrease in GABAergic inhibition, 
facilitating seizures. Recently published results by Lavaque et al (2006) suggest age-related 
focal production of sex hormones especially prominent in the hippocampus and cerebral 
cortex. The expression of the steroidogenic acute regulatory protein was found to increase 
particularly in these areas. The hippocampus and cerebral cortex are areas associated with 
seizure initiation and propagation. It is therefore discussed how pathological disturbances 
in the local estrogen production after menopause may contribute to an increase in seizures 
in some women (Veliskova, 2007). 
Estrone is the primary estrogen after menopause, and its main source is subcutaneous fat. 
This might be of importance for overweight women with epilepsy. Little is known on the 
influence of estrone on epilepsy. An altered ratio of estradiol/estriol/estrone might be of 
importance; however, this has not been investigated. Most likely, however, the hormonal 
changes in menopause may not affect the different types of epilepsy in the same way. 
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Fig. 1. Three patterns of catamenial epilepsy. During normal ovulatory cycles, both 
perimenstrual (C1) and periovulatory (C2) patterns can occur in isolation or together. 
During inadequate luteal phase cycles, the (C3) pattern can occur with increased seizures 
during the entire second half of the cycle. (Herzog AG. Catamenial epilepsy: definition, 
prevalence pathophysiology and treatment. Seizure 2008;17:151) 
www.intechopen.com
 
Novel Aspects on Epilepsy 
 
56
Reproductive dysfunction is common among women with epilepsy primarily due to the 
dysfunction in the temporolimbic system. This system has integral roles in reproductive 
endocrine regulation and feedback as well as in sexual and reproductive function (Herzog, 
1989). Consequently, the development of epileptiform discharges in medial temporal lobe 
structures may disrupt hypothalamic regulation of pituitary secretion and, hence, alter 
gonadal function.  
In addition, most of the AEDs (carbamazepine, oxcarbazepine, phenobarbital, phenytoin, 
and topiramate) may also alter endocrine function by inducing the cytochrome P450 
isoenzyme 3A4 in women with epilepsy (Luef, 2009). Therefore, certain AEDs may 
accelerate hepatic elimination of hormonal preparations and decrease the serum 
concentrations of bioactive sex steroids.  
Epileptic women have increased risk of polycystic ovary syndrome (PCOS), premature 
ovarian failure (POF), and hormonal contraceptive failure; as well as osteoporosis (Figure 2). 
 
 
Fig. 2. Possible changes in epileptic women according to different stages of female life 
AED, anti-epileptic drug; PCOS, polycystic ovary syndrome. 
2. Epilepsy and polycystic ovary syndrome 
PCOS is characterized by enlarged ovaries with multiple small cysts and a 
hypervascularized, androgen-secreting stroma leading to the associated signs of androgen 
excess (hirsutism, alopecia, acne), obesity, and menstrual-cycle disturbance (oligo or 
amenorrhea) (Balen, 1999). The most common reproductive endocrine disorder in women 
with epilepsy, as well as in women in the general population, is PCOS. PCOS occurs in 10-
20% of women with epilepsy compared to 5-6% of women in the general population (Bauer 
et al, 2008; Knochenhauer et al, 1998; Herzog, 2002; Herzog et al, 2003). The prevalence of 
PCOS in women with epilepsy is greater, even if they are not taking AEDs; and it is more 
frequent in women who take valproic acid (VPA), primarily if initiated before the age of 20. 
PCOS is probably not a single nosological entity, but rather the common endpoint for a 
number of pathophysiological mechanisms, some of which may be attributable to epilepsy 
itself (Herzog et al, 1986, 2003) or to the use of AEDs, most notably valproate. PCOS 
represents the failure of the ovarian follicle to complete normal maturation during the 
menstrual cycle or a series of cycles -- a failure that is perhaps related to the presence of 
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inadequate levels of pituitary follicle-stimulating hormone (FSH); whereas levels of 
luteinizing hormone (LH) are normal or elevated (Isojärvi, 2008; Herzog, 2008).  
The brain controls reproductive function primarily through hypothalamic regulation of 
pituitary secretion. The left and right vagus nerves exert different modulatory influences on 
ovarian structure and function (Gerendai & Halasz, 1997). The reproductive neuroendocrine 
system, like many other brain systems, shows a lateralized asymmetry that might, by virtue 
of ipsilaterally predominating effects, contribute to the development of distinct reproductive 
endocrine disorders in association with unilateral left- and right-sided epileptic foci 
(Herzog, 2007). Unilateral temporolimbic discharges are associated with laterally differing, 
consistent, predictable, stochastic directional changes in hormonal secretion at all levels of 
the reproductive neuroendocrine axis, that is, hypothalamus, pituitary, and ovary (Herzog 
et al, 2003). These directional changes are consistent with the finding that different 
reproductive disorders may develop in relation to left- and right-sided temporolimbic 
epilepsy. Specifically, left temporal lobe epilepsy (LTLE) is associated with significantly 
higher pulse frequencies of GnRH secretion (Herzog et al, 2003; Herzog, 2008). Higher 
GnRH pulse frequency, in turn, is associated with higher LH/FSH ratios and higher serum 
testosterone levels. This combination of neuroendocrine changes characterizes PCOS and is 
consistent with the previously suggested association between left unilateral TLE and PCOS. 
Antiepileptic drugs, on the other hand, also have substantial and differential effects on 
reproductive hormone levels. The first report suggesting a high incidence of menstrual 
disorders linked to obesity, hyperandrogenism, and polycystic ovaries in women taking 
VPA for epilepsy was published in 1993 (Isojarvi). Changes in serum androgen levels have 
been detected before and during pubertal development in young girls taking VPA for 
epilepsy (Vainionpää, 1999). 
Studies by Murialdo et al (1997) have also reported a high prevalence of menstrual disorders 
and hyperandrogenic anovulation in VPA treated women with epilepsy. However, the 
study by Bauer et al (2008) did not show any differences between carbamazepine- and VPA-
treated women with epilepsy with respect to reproductive endocrine parameters. Although  
the interpretation of the results of this study is difficult, because the age of the patients, the 
duration of medication, and seizure frequency in the different treatment groups were not 
given (Isojärvi, 2005). Other studies have also addressed the issue of reproductive endocrine 
function in women with epilepsy. Luef et al (2002) reported similar frequencies of menstrual 
disorders and PCOS in women taking carbamazepine and VPA for epilepsy. It has been 
suggested that obesity and associated hyperinsulinemia could be implicated in the 
development of PCOS and hyperandrogenism in women taking VPA. It seems that obesity 
and related hyperinsulinemia may exacerbate the VPA-related reproductive endocrine 
disorders in women with epilepsy. It seems likely that VPA has a direct effect on ovarian 
androgen production, or as an enzyme inhibitor, it may inhibit the metabolism of sex 
steroids and thereby lead to increased serum androgen levels (Isojärvi et al, 2005).  
Several studies have suggested that the reproductive endocrine effects of AEDs may be 
reversible if the medication is discontinued. In a prospective study, the replacement of VPA 
with lamotrigine resulted in normalization of endocrine function during a 1-year follow-up 
in 12 women with a previously identified endocrine disorder (PCOS or hyperandrogenism, 
or both) likely to be related to VPA. Serum insulin and testosterone levels returned to 
normal 2 months after VPA was discontinued, and the levels remained normal thereafter 
(Isojärvi et al, 2005).  
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3. Epilepsy and premature ovarian failure 
POF is characterized by amenorrhea, cessation of ovarian function, and elevated 
gonadotropin levels before 35 years of age and younger. Ovarian failure due to POF may 
not be absolute; hence, this condition needs to be differentiated from premature menopause 
because the latter reflects a ‘‘permanency’’ of the ovarian failure.  
Indeed, women with POF often continue to have some residual ovarian function for many 
years after diagnosis (Kodaman, 2010, Kalantaridou&Nelson 2000). Both sporadic ovulation 
and occasional pregnancy are possible with POF; (Nelson et al, 1994, Alper et al, 1986) in 
fact; up to half of women affected by POF have intermittent follicular development, 25% 
may occasionally ovulate, and 5 to 10% will conceive and deliver (Nelson et al, 1994, 
Rebar&Connolly, 1990, Rebar, 2009). The term menopause thus should be avoided in the 
context of counseling these patients, and more recently, the term POF has also fallen into 
disfavor because it implies finality and gives a further negative connotation to an already 
devastating diagnosis for a young woman to come to terms with. POF, the term first coined 
by the endocrinologist Fuller Albright almost 70 years ago, is now the preferred 
nomenclature for this entity. (Albright et al, 1942, Welt, 2008, Nelson, 2009) The incidence of 
POF increases with age, affecting 0.01%, 0.1%, and 1% of women <20, 30, and 40 years of 
age, respectively (Coulam, 1986). Given the association of chemoradiation therapy with 
subsequent ovarian insufficiency and the increasing successes with childhood and early 
adulthood malignancy treatments, it has been predicted that the number of cases of POF 
will increase significantly in the future (Sklar, 2006, Panay&Fenton, 2008). Etiologies for POF 
are heterogeneous and, for the most part, poorly understood. The etiology for up to 90% of 
cases of POF remains elusive (Kodaman, 2010). 
POF occurs more commonly in women with epilepsy. Klein et al (2001) evaluated the 
incidence of POF in 50 women with epilepsy, aged 38 to 64, compared with control women. 
Premature menopause was defined as amenorrhea for greater than 1 year with elevated day 
3 FSH levels in women younger than 42 years. Premature perimenopause was defined by 
the presence of perimenopausal symptoms. Of the women with epilepsy, 14% had 
premature perimenopause or menopause, compared with only 3.7% of the control women 
(P = 0.042). They did not find an association with epilepsy duration, seizure severity, or 
AEDs; although women with premature menopause were more likely to have had 
catamenial exacerbation of their seizures than women without POF (P = 0.02). Harden et al 
(2003) also found in their multicentric cohort study that premature menopause was 
associated with epilepsy. In another study, the median age at menopause in the group of 
women with epilepsy was 47 years, compared with the median age of 51.4 years in the 
general US population (Gold, et al, 2001). When the investigators divided the patients into 
low, intermediate, and high seizure frequency groups, there was an increasingly lower age 
at menopause with a negative correlation between the age at menopause and seizure group 
based on estimated lifetime seizures (P = 0.014). They also found no influence of enzyme-
inducing AEDs. The authors concluded that the association of lifetime number of seizures 
with the timing of cessation of reproductive cycling may occur as a result of direct 
disruption of hypothalamic and pituitary function by the seizures.  
Women with epilepsy have an increased risk of experiencing an early onset of 
perimenopausal symptoms. Some studies draw attention to the increased frequency of POF 
in women with epilepsy. However, no association has been detected so far between the POF 
and epilepsy duration, seizure severity, or use of enzyme-inducing AEDs. POF may occur as 
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a result of direct disruption of hypothalamic and pituitary function by the seizures. It has 
been suggested that women with POF were more likely to have catamenial exacerbation of 
their seizures than women without POF.  
4. Contraception and epilepsy 
Contraceptive methods can be divided into two subgroups as hormonal and non-hormonal. 
Hormonal contraceptives include combined-oral contraceptives, progestin only pills, 
hormonal implants, progestin releasing intrauterine systems, depomedroxyprogesterone 
acetate injections, and vaginal rings. Non-hormonal contraceptive methods include male and 
female condoms, copper intrauterine device, tubal ligation and vasectomy of the companion. 
Combined oral contraceptives are a widely used and well accepted form of contraception. 
Combined-oral contraceptives are highly effective when used consistently and correctly, 
and are well tolerated by most women. Combined-oral contraceptives contain a 
combination of an estrogen and a progestin. Since their introduction, several progestins 
have been developed for use in combined-oral contraceptives. Conversely, the estrogen 
component has remained largely unchanged, with the vast majority of combined-oral 
contraceptives containing ethinylestradiol (EE) or, more commonly in the past, mestranol, 
the 3-methyl ether of EE. The estrogen component of combined-oral contraceptives is 
responsible for suppressing FSH, providing endometrial stability, and potentiating the 
activity of the progestin component, e.g., by increasing progestin receptor concentrations. 
However synthetic progestins may directly influence ovarian function by a direct inhibition 
of the ovarian steroid biosynthesis. Modern combined-oral contraceptives have two 
components: EE and a progestin. Both are on their own able to inhibit ovulation. In  
modern combined-oral contraceptives ovulation inhibition is mainly achieved by the 
progestin and not by ethinylestradiol. The typical daily progestin dose in today’s  
combined-oral contraceptives is about 1.5—2 times the ovulation-inhibiting dose 
(Schwenkhagen&Stodieck, 2008). 
The choice of a contraceptive drug can be challenging for women with epilepsy due to 
possible interactions between AEDs and hormonal contraception. Enzyme-inducing AEDs 
can cause hormonal contraception to fail and can increase the risk of teratogenicity. Higher 
doses of oral contraceptives can overcome pharmacologic failure but may create additional 
risks (Burakgazi et al, 2009). 
In women with epilepsy failure rates of oral contraceptives may increase to 6% depending 
on the antiepileptic drug they are taking (Morell, 1996). Drugs such as phenobarbital (PB), 
primidone (PRM), phenytoin (PHT), carbamazepine (CBZ), oxcarbazepine (OXC) at doses 
above 600 mg daily and topiramate (TPM) at doses above 200 mg (Doose et al, 2003) may 
cause induction of hepatic cytochrome P450, reducing the effects of contraceptives to block 
ovulation. VPA and felbamate (FBM) inhibit the hepatic microsomal system and do not 
reduce, and can even increase, the levels of the steroid hormones of oral contraceptives. 
Other drugs such as gabapentin (GBP), lamotrigine (LTG), tiagabine (TGB), pregabalin 
(PGB), vigabatrin (VGB), and levetiracetam (LEV) do not affect the serum concentrations of 
contraceptives (Tatum et al, 2004) (Table 1). To avoid lack of efficacy of contraception used 
in a patient that is on therapy with enzyme-inducing AEDs when the “morning-after pill” is 
used at the same time, the first dose of levonogestrel should be 1.5 mg (twice the usual dose 
of 750 μg), and after 12 hours the recommended 750 μg are reinstated (Mayor, 2004; Perruca, 
2004). Moreover, oral contraceptives can reduce levels of LTG by 25% to 70%. If the woman 
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is taking AEDs, which reduce steroid hormone levels, oral contraceptives must contain a 
minimum of 50 μg of EE. If there is a hemorrhage, the dose should be raised to 75 or 100 μg. 
During the first months of oral contraceptive use, and once ovulation has been eliminated, 
complementary contraceptive methods are recommended. To improve contraceptive 
efficacy, the use of a combined-oral contraceptives that contains a progestin well above the 
dose needed to inhibit ovulation may be recommended. Ovulation-inhibiting doses of 
progestins are given in table 1. 
 
Progestin mg/day 
Chlormadinone acetate 1.7 
Cyproterone acetate 1.0 
Desogestrel/3-keto-desogestrel 0.06 
Dienogest 1.0 
Drospirenone 2.0 
Gestodene 0.04 
Levonorgestrel 0.06 
Norethisterone 0.4 
Norethisterone acetate 0.5 
Nomegestrol acetate 5.0 
Table 1. Ovulation-inhibiting doses of progestins (without additional estrogen) (Kuhl, 2005) 
Commonly used AEDs which do and do not interact with oral contraceptives are given in 
Table 2.  
 
Drugs which do not reduce the effects 
of oral contraceptives 
Drugs which reduce the effects of 
oral contraceptives 
Clonazepam Barbiturates 
Ethosuximide Carbamazepine 
Felbamate Oxcarbazepine 
Gabapentin Phenytoin 
Levetiracetam Primidone 
Lamotrigine Topiramate (>200 mg/day) 
Tiagabine  
Valproate  
Table 2. Commonly used AEDs which do and do not interact with oral contraceptives 
Most drug—drug interaction studies have focused on the effect of AEDs on oral 
contraceptive safety. Much less is known about the result of a co-prescription of hormonal 
contraceptives on AEDs, which is surprising, since it is known for a long time that oral 
contraceptives have a strong influence on drug metabolizing enzymes. 
(Schwenkhagen&Stodieck, 2008). 
In combined oral contraceptives, during the period ‘‘on the pill’’ lamotrigine levels decrease 
by approximately 50%, followed by an increase of lamotrigine levels in the contraceptive-
free week up to 80— 100% of the baseline lamotrigine level. This is often clinically relevant 
and may result in an increased risk of seizure recurrence especially in week 2 and 3 on the 
pill or in concentration-dependent adverse effects at the end of the pill-free interval (Sabers 
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et al, 2001, 2003; Stodieck &Schwenkhagen, 2004; Christensen, 2007). These fluctuations are 
most likely due to an induction of UGT1A4, the enzyme responsible for the glucoronidation 
of lamotrigine, by EE. VPA levels also seem to be reduced by the concomitant use of 
hormonal contraceptives (Herzog et al, 2005; Galimberti, 2006). Just as with lamotrigine the 
magnitude of observed fluctuations of the VPA levels appear to vary interindividually. 
Hormonal contraceptives which are adversely affected by hepatic cytochrome P450 enzyme-
inducing AEDs are given in Table 3. 
 
Oral  
Various combined estrogen/progesterone preparations 
Progestin only pill 
Morning after pill 
Transdermal patch (norelgestromin and ethinyl estradiol)  
Vaginal ring (etonorgestrel/ethinyl estradiol ring) 
Implants (etonorgestrel) 
Table 3. Hormonal contraceptives which are adversely affected by hepatic cytochrome P450 
enzyme-inducing AEDs 
In addition to induction of cytochrome P450 enzyme system, several AEDs induce the 
production of sex hormone binding globulin (SHBG) to which the progestins are tightly 
bound, resulting in lower concentrations of free progestin that may also lead to combined-
oral contraceptive failure (Dutton C, Foldvary-Schaefer, 2008). 
While higher dose combined-oral contraceptives are one contraceptive option for women on 
enzyme-inducing AEDs, a variety of other options are available. Injectable contraception 
(depot medroxyprogesterone acetate) appears effective with AED use, but the potential for 
bone mineral density loss is a concern. (Dutton C, Foldvary-Schaefer, 2008) 
Non-hormonal contraceptive methods are not contraindicated in women with epilepsy. If 
contraception is addressed as a permanent measure, the safest method is tubal ligation or 
vasectomy of the companion. Intrauterine devices are an alternative to pharmacologic 
approaches because they lack drug-drug interactions and side effects (Burakgazi et al, 2009). 
There is no evidence that combined-oral contraceptives increase seizures in women with 
epilepsy (Dutton C, Foldvary-Schaefer, 2008). 
5. Epilepsy and menopause 
Ovarian reserve shrinks throughout life and reaches a critical threshold level at the 
inception of the menopause. At this point, a woman notes her first skipped menstrual 
period. The menopausal transition begins with the onset of first menstrual irregularity, or 
skipped menses, and ends with the final menstrual period. Progressive loss of ovarian 
follicles results in decreased production of inhibin and a loss of restraint on FSH secretion. 
The monotropic increase in FSH leads to variable hormonal patterns, depending on the 
available ovarian follicles and their degree of responsiveness. Once follicles reach a critically 
low level, ovulation becomes progressively less likely and prolonged amenorrhea ensues. In 
addition to ovarian factors that contribute to reproductive senescence in women, there is 
accumulating evidence that as in rodents, hypothalamic-pituitary dysfunction accompanies 
reproductive aging and contributes to the process. As knowledge about the menopausal 
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transition increases, it may turn out that the ovary is not the only area that should be 
studied—the brain may undergo changes as well (Santoro, 2005). 
During the perimenopausal period, the frequency of catamenial epileptic seizures may 
increase (probably due to hyperestrogenism) and then decrease after menopause. According 
to current data, hormone replacement therapy (HRT) may increase the frequency of 
epileptic seizures. Changes in serum concentrations of sex steroid hormones are frequently 
observed when enzyme-modulating AEDs (VPA, CBZ, phenytoin, or phenobarbital) are 
used. It is generally accepted that long-term treatment with VPA and CBZ may lead to 
reproductive endocrine disorders in patients with epilepsy. VPA can increase biologically 
active sex hormone levels (e.g., hyperandrogenism) independent of associated weight gain, 
more commonly seen in women before the age of 20. In contrast, CBZ may decrease free 
serum testosterone concentrations through the induction of SHBG. If the woman is taking 
AEDs, which reduce steroid hormone levels, OCs must contain a minimum of 50 μg of EE. If 
there is a hemorrhage, the dose should be raised to 75 or 100 μg. 
Indications for HRT are dealing with menopausal symptoms and conservation of bone mass 
and fracture prevention. As epilepsy is affected by sex steroids, careful consideration must 
be given to the regimen used. However, the data are extremely limited (Harden et al, 2006; 
Shen & Stearns 2009). The details of the only randomized trial double-blind, placebo-
controlled trial are now described (Harden et al, 2006). This was undertaken in 
postmenopausal women with epilepsy who are taking stable doses of AEDs and are within 10 
years of their last menses. After a 3-month prospective baseline, subjects were randomized to 
placebo, Prempro (0.625 mg of conjugated equine estrogens plus 2.5 mg of 
medroxyprogesterone acetate or CEE/MPA) daily, or double-dose CEE/MPA daily for a 3-
month treatment period. Twenty-one subjects were randomized after completing baseline. The 
subjects’ ages ranged from 45 to 62 years (mean, 53 years), and the number of AEDs used 
ranged from none to three (median, one). Five (71%) of seven subjects taking double-dose 
CEE/MPA had a worsening seizure frequency of at least one seizure type, compared with four 
(50%) of eight taking single-dose CEE/MPA, and one (17%) of six taking placebo (p = 0.05). An 
increase in seizure frequency of the subject’s most severe seizure type was associated with 
increasing CEE/MPA dose (p = 0.008). An increase in complex partial seizure frequency also 
was associated with increasing CEE/MPA dose (p = 0.05). Two subjects taking lamotrigine 
had a decrease in lamotrigine levels of 25–30% while taking CEE/MPA. The authors 
concluded that CEE/MPA is associated with a dose-related increase in seizure frequency in 
postmenopausal women with epilepsy. CEE/MPA may decrease lamotrigine levels. There are 
no data with other regimens with different estrogens and progestogens or transdermal or 
vaginal administration. It is not known whether women with epilepsy need higher doses of 
estrogen or whether transdermal rather than oral therapy is preferred depending on their AED 
use. Based on the randomized trial, it would be prudent to closely monitor women who start 
HT as their AED needs may change (Erel et al, 2010).  
Non-estrogen based treatments are used to treat hot flushes and symptoms of urogenital 
atrophy (Erel et al, 2010). Drug interactions need to be carefully assessed before using 
pharmacotherapy. Interventions to consider include clonidine, selective serotonin reuptake 
inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs), gabapentin, 
and vaginal lubricants and mosturizers (Shen et al, 2009). While bisphosphonates will 
conserve bone mass, there are little data in women with epilepsy and there are concerns 
about the safety of long term use (Drezner, 2004).  
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As vitamin D and calcium metabolism can be affected by AEDS, supplements should be 
considered. Herbal preparations should be avoided as their efficacy is uncertain and they 
may interact with AEDs (Erel et al, 2010). 
6. Epilepsy and osteoporosis 
The cessation of ovarian function at the menopause is associated with a phase of rapid bone 
loss which probably lasts from 5 to 10 years (Genant et al, 1982; Recker et al, 2000). This 
rapid bone loss results from an increase in bone turnover in association with a negative 
remodelling imbalance (Compston, 2001); whilst reduced bone formation undoubtedly 
contributes to the latter, there is evidence that increased osteoclastic activity also plays a 
role, particularly in the earlier stages of menopausal bone loss (Compston et al, 1995). The 
combination of increased bone turnover and increased resorption depth results in 
disruption of bone microarchitecture, with loss of connectivity of cancellous bone and 
thinning of the cortices, which also show increased porosity. 
Osteoporosis and fractures may increase due to hypoestrogenism in menopause and 
cytochrome P450 inducing AEDs. Recent studies suggest lower bone mineral density (BMD) 
in adults and children with epilepsy, irrespective of AED treatment.  
Both idiopathic epilepsy and symptomatic epilepsy are associated with reduced BMD, with 
the greatest reduction in symptomatic generalized epilepsy (Sheth & Hermann, 2008). 
However, the pathophysiological underlying mechanisms are far from understood and likely 
multifactorial. Potential risk or predisposing factors include physical impairment, genetic 
factors, AED treatment with enzyme-inducing drugs, AED polytherapy, impact of seizures on 
the hypothalamus-hypophysis-adrenal (HPA) axis, and vitamin D deficiency/insufficiency. 
As growth and sexual maturation in adolescence are regulated by a complex neuroendocrine 
system including the HPA axis, potential AED-related abnormalities may be reflected in 
growth and bone metabolism in childhood epilepsy. In adults and children treated with 
enzyme-inducing AEDs, vitamin D deficiency/insufficiency (up to 50% of patients) and low 
BMD have been reported in most, but not all, studies (Petty et al, 2007; Farhat et al, 2002; Pack 
et al, 2005; Verrotti et al, 2000).  
However, and in particular in children, it is unclear whether non-enzyme-inducing AED 
monotherapy (lamotrigine, sulthiame) or minimal enzyme-inducing AED monotherapy 
(oxcarbazepine) seem to have any adverse effects on linear growth or to cause vitamin D 
deficiency in otherwise healthy children with epilepsy (Luef & Rauchenzauner, 2008). In 
contrast to adults, there is controversy over the association of chronic AED use with an 
increased incidence of fractures in children (Souverein et al, 2005; Petty, et al, 2007). Recent 
studies suggest lower BMD in adults and children with epilepsy, irrespective of AED 
treatment (Pack, 2008; Sheth et al, 2008a, 2008b; Pack & Walczak, 2008; Sheth & Hermann, 
2008). 
7. Conclusion 
In conclusion, in gynecological practice, women with epilepsy deserve special care with a 
multidisciplinary approach. Women with epilepsy should be questioned routinely about 
menstrual cycles, infertility, excessive weight gain, hirsutism, galactorrhea, and changes in 
sexual life. If abnormalities are detected, hormone determinations, pelvic ultrasound, and 
neuroimaging of pituitary gland should be assessed. If the cause of the problem is AED-
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related, a therapeutic alternative should be addressed, taking into account seizure control 
possibilities versus side effects.  
Seizures generally exacerbate during the 3 different periods of the menstrual cycle: in 
perimenstrual and periovulatory periods in normal cycles, and in inadequate luteal phase in 
abnormal cycles. This type of epilepsy is defined as catamenial epilepsy and is under the 
influence of estrogen and progesterone. Estrogen has been shown to increase seizure 
activity, while progesterone decreases it by raising the seizure threshold level. 
The prevalence of PCOS in women with epilepsy is 10-20%, which is greater than the 
normal population, even if epileptic women are not taking AEDs. PCOS is more frequent in 
women who take VPA, primarily if initiated before the age of 20. 
Women with epilepsy have an increased risk of experiencing an early onset of 
perimenopausal symptoms. Some studies draw attention to the increased frequency of POF 
in women with epilepsy, although this relationship needs to be further investigated. 
In women with epilepsy, failure of oral contraceptives may increase to 6% depending on the 
antiepileptic drug they are taking. Barbiturates, Carbamazepine, Oxcarbazepine, Phenytoin, 
Primidone, and Topiramate (>200 mg/day) may reduce the efficacy of oral contraceptives. 
Clonazepam, Ethosuximide, Felbamate, Gabapentin, Levetiracetam, Lamotrigine, Tiagabine, 
and VPA do not seem to interact with oral contraceptives. During the first months of oral 
contraceptive use, and once ovulation has been eliminated, complementary contraceptive 
methods are recommended. Non-hormonal contraceptive methods are not contraindicated 
in women with epilepsy. There is no evidence that combined-oral contraceptives increase 
seizures in women with epilepsy.  
During menopause, 27% of the epileptic women had improvement, 33% did not modify 
their seizure pattern, and 40% worsened. Monitoring for osteoporosis is recommended, 
particularly if treatment is with AEDs which reduce steroid hormone levels. According to 
the The European Menopause and Andropause Society (EMAS) position statement, epileptic 
women starting hormone therapy should be closely monitored as their AED needs may 
change; calcium and vitamin D supplements should be considered, and herbal preparations 
should be avoided as their efficacy is uncertain and they may interact with AEDs (Erel et al, 
2010). 
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